Gal D, Edman C D, Vellios F, Forney J P
Am J Obstet Gynecol. 1983 Jun 1;146(3):316-22. doi: 10.1016/0002-9378(83)90754-8.
Fifty-two postmenopausal women who were poor surgical risks and had histologically proved adenomatous hyperplasia, atypical hyperplasia, or adenocarcinoma in situ of the endometrium were treated with megestrol acetate, 40 mg per day, continuously for 9 to 104 months (mean, 42 months). More than 90% of these women had complete remissions of the hyperplasia. Three women with carcinoma in situ were followed up for 57, 65, and 104 months, without recurrence of the disease. Four women required hysterectomy; none had invasive adenocarcinoma. No adverse side effects of the drug were observed. Thus, we conclude that the continuous use of megestrol acetate is an effective, safe, alternative form of therapy for endometrial hyperplasia in postmenopausal women.
52名手术风险高的绝经后女性，其子宫内膜经组织学证实有腺瘤样增生、非典型增生或原位腺癌，接受醋酸甲地孕酮治疗，每天40毫克，持续9至104个月（平均42个月）。这些女性中超过90%的增生完全缓解。3名原位癌女性随访了57、65和104个月，疾病无复发。4名女性需要进行子宫切除术；均无浸润性腺癌。未观察到该药物的不良副作用。因此，我们得出结论，持续使用醋酸甲地孕酮是绝经后女性子宫内膜增生的一种有效、安全的替代治疗方式。
